Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 5:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 640 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ketamine Clear all
Completed Phase 4 Interventional Results available

Effect of Postoperative Single Dose of Ketamine on Pain After Mastectomy

NCT04831736
View directory record Official record
Conditions
Postoperative Pain
Interventions
Ketamine, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Oct 17, 2026, 5:20 PM EDT
Completed Phase 3 Interventional Results available

Ketamine for Postoperative Avoidance of Depressive Symptoms: The K-PASS Feasibility Trial

NCT05233566
View directory record Official record
Conditions
Postoperative Depression
Interventions
Ketamine, Normal saline
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 17, 2026, 5:20 PM EDT
Terminated Phase 2 Interventional Results available

Reducing Adolescent Suicide Risk: Safety, Efficacy, and Connectome Phenotypes of Intravenous Ketamine

NCT04613453
View directory record Official record
Conditions
Adolescent Suicide, Adolescent Depression
Interventions
Ketamine Infusion, Midazolam Infusion
Drug
Lead sponsor
Yale University
Other
Eligibility
13 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 17, 2026, 5:20 PM EDT
Completed No phase listed Observational

Long Term Follow Up KET-PD

NCT06164756
View directory record Official record
Conditions
Parkinson's Disease, Depression
Interventions
Cognitive Behavior Therapy (CBT), Treatment As Usual (TAU)
Other
Lead sponsor
Yale University
Other
Eligibility
40 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 17, 2026, 5:20 PM EDT
Terminated Phase 2 Interventional

Ketamine for OUD and Suicidal Ideation in the ED

NCT06111339
View directory record Official record
Conditions
Opioid Use Disorder, Suicidal Ideation
Interventions
Ketamine, Saline Solution
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 17, 2026, 5:20 PM EDT
Completed Phase 2 Interventional Results available

IN Sub-Dissociative Ketamine vs IN Fentanyl

NCT02521415
View directory record Official record
Conditions
Bone Fracture
Interventions
ketamine, fentanyl, ibuprofen or acetaminophen
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
4 Years to 17 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 17, 2026, 5:20 PM EDT
Enrolling by invitation Not applicable Interventional

Psychotherapy Combined With Intranasal Esketamine for the Treatment of Suicidal Ideation

NCT07396220
View directory record Official record
Conditions
Suicidal Ideation
Interventions
Naturalistic Intranasal Esketamine, Brief Cognitive Behavioral Therapy for Suicide Prevention
Other · Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 70 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 17, 2026, 5:20 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder

NCT03065335
View directory record Official record
Conditions
Healthy Volunteer, Major Depressive Disorder, Depression
Interventions
Ketamine, Placebo, Cobot TS MV robotic arm for TMS, NeurOptics PLRTM-30000 Pupillometer
Drug · Other · Device
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 17, 2026, 5:20 PM EDT
Withdrawn Phase 4 Interventional

A Randomized, Double-Blind Study of Placebo vs. Ketamine For Use During Dressing Changes in Critically Ill Burn Patients

NCT02336308
View directory record Official record
Conditions
Thermal Hyperalgesia, Anxiety, Pain
Interventions
Ketamine, Placebo, Normal Saline
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 26, 2015 · Synced Oct 17, 2026, 5:20 PM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Intraoperative Low-dose Ketamine Infusion for Patients With Obstructive Sleep Apnea

NCT03109418
View directory record Official record
Conditions
Sleep Apnea, Obstructive Sleep Apnea, Postoperative Complications
Interventions
Ketamine, Control
Drug · Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 100 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 19, 2019 · Synced Oct 17, 2026, 5:20 PM EDT
Completed Phase 2 Interventional Results available

A Study of Ketamine in Patients With Treatment-resistant Depression

NCT01627782
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, Ketamine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Centennial, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 17, 2026, 5:20 PM EDT
Not listed Phase 4 Interventional

Ketamine v. Ketorolac for Management of Generalized Tension Type Headache

NCT03221569
View directory record Official record
Conditions
Migraine
Interventions
Intravenous ketamine, Ketorolac, Normal saline
Drug
Lead sponsor
The Brooklyn Hospital Center
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jul 6, 2018 · Synced Oct 17, 2026, 5:20 PM EDT
Completed Phase 1 Interventional

Modified Ketogenic Diet and Ketamine for Anorexia Nervosa

NCT04714541
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
Ketamine Hcl 50Mg/Ml Inj
Drug
Lead sponsor
Homeostasis Therapeutics, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
South Windsor, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Oct 17, 2026, 5:20 PM EDT
Completed Phase 1 Interventional

Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response, Pilot Trial

NCT03367533
View directory record Official record
Conditions
Depressive Disorder, Major, Post Traumatic Stress Disorder, Bipolar Disorder
Interventions
Ketamine, Perampanel, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 17, 2026, 5:20 PM EDT
Completed Phase 1 Interventional

Study of Intranasal Ketamine for Social Impairment in Autism Spectrum Disorder

NCT02611921
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Ketamine, Placebo
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years to 30 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 17, 2026, 5:20 PM EDT
Completed Phase 4 Interventional

Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression

NCT05615948
View directory record Official record
Conditions
Treatment Resistant Depression, Major Depressive Disorder, Analgesia, Ketamine, Peripheral Nervous System Agents, Central Nervous System Depressants, Neurotransmitter Agents, Anti-Inflammatory Agents, Physiological Effects of Drugs, Sensory System Agents, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Non-Steroidal, Depressive Symptoms
Interventions
VTS-K
Drug
Lead sponsor
Theresa Jacob, PhD, MPH
Other
Eligibility
18 Years to 89 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 17, 2026, 5:20 PM EDT
Active, not recruiting Phase 2 Interventional

Enhancing Week-long Psychological Treatment for PTSD With Ketamine

NCT05737693
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 70 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 17, 2026, 5:20 PM EDT
Completed Phase 2 Interventional Results available

Ketamine Plus Lithium in Treatment-Resistant Depression

NCT01880593
View directory record Official record
Conditions
Depression
Interventions
Lithium, Ketamine, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 17, 2026, 5:20 PM EDT
Recruiting Phase 4 Interventional

Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression

NCT05450432
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ketamine, Esketamine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 17, 2026, 5:20 PM EDT
Completed Phase 4 Interventional Results available

A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression

NCT04599855
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine 56 mg, Esketamine 84 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
54
States / cities
Birmingham, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2025 · Synced Oct 17, 2026, 5:20 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Facilitating Rapid Naltrexone Initiation

NCT03345173
View directory record Official record
Conditions
Opioid Dependence
Interventions
CI-581-a, CI-581-b
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 2, 2024 · Synced Oct 17, 2026, 5:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Electrophysiology, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response Using Magnetic Resonance Imaging of SAGE-718 Using a Ketamine Challenge in Healthy Subjects

NCT03770780
View directory record Official record
Conditions
Healthy Volunteer
Interventions
SAGE-718, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Long Beach, California • Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 17, 2026, 5:20 PM EDT
Completed Phase 1 Interventional

Oral Ketamine for Treatment of Vaso-Occlusive Pain

NCT05378555
View directory record Official record
Conditions
Vaso-occlusive Crisis
Interventions
Ketamine Hydrochloride
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
12 Years to 24 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 17, 2026, 5:20 PM EDT
Not yet recruiting Phase 4 Interventional

Understanding the Role of the Kappa Opioid Receptor in Ketamine's Attenuation of Suicidal Thoughts

NCT07139106
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Ketamine hydrochloride infusion
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 59 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 17, 2026, 5:20 PM EDT